An Open Letter to the New York Times on Cannabis, Responsibility, and Reality
To the Editorial Board of The New York Times,
We read your recent editorial on marijuana legalization carefully. Not casually. Not defensively. Carefully.
Silly Nice exists because of lived experience with cannabis, not because of trends, lobbying, or hype. We agree with you on one point without hesitation: cannabis is not harmless. Any substance that alters consciousness carries risk, and adults deserve honest information about those risks.
Where we strongly disagree is in how your editorial frames cannabis as a uniquely troubling public health problem while failing to apply the same standards, context, and proportionality to alcohol and tobacco. That imbalance matters, especially coming from an institution with your reach and influence.
This response is not about protecting an industry. It is about protecting truth, perspective, and the people most affected by policy decisions.
Context Matters in Public Health Discussions
Any serious discussion of substance use must begin with proportional harm.
Alcohol remains one of the most destructive legal substances in the United States. According to the Centers for Disease Control and Prevention, alcohol contributes to roughly 178,000 deaths each year through liver disease, cancer, cardiovascular disease, accidents, violence, and alcohol poisoning.
Tobacco is even more devastating. Cigarette smoking is responsible for more than 480,000 deaths annually, making it the leading cause of preventable death in the country. These deaths are slow, painful, and well documented.
Cannabis does not belong in the same category of mortality risk. There is no credible evidence of fatal overdose caused by cannabis alone. That does not make cannabis harmless. It makes it categorically different.
Your editorial discusses cannabis as if increased use automatically signals increased societal danger. That assumption does not hold up when examined alongside real-world outcomes.
Frequency of Use Is Not the Same as Severity of Harm
You point out that more Americans now use cannabis daily than alcohol. That statistic is presented as self-evident cause for alarm.
It is not.
Many substances are used daily without triggering moral panic or public health emergencies. Caffeine is used daily by a majority of American adults. Prescription medications are taken daily by tens of millions of people. Alcohol itself is used daily by many without incident.
Frequency alone tells us nothing without context. What matters is what happens to people who use a substance and what harm results to them and others.
On that front, cannabis continues to rank lower than alcohol and tobacco across metrics including mortality, violence, long-term disease burden, and family disruption. Treating daily cannabis use as inherently more troubling than daily alcohol use reflects cultural bias, not data-driven analysis.
Cannabinoid Hyperemesis Syndrome Deserves Accuracy, Not Amplification
Your editorial cites cannabinoid hyperemesis syndrome as evidence of widespread harm. CHS is real. It affects a subset of heavy, long-term users. It can be debilitating.
It is also rare relative to total cannabis use and almost always resolves with cessation. It does not cause death. It does not result in permanent organ damage. It is not comparable to cirrhosis, emphysema, or cancer.
Using CHS as a central argument while minimizing alcohol-related gastrointestinal disease and tobacco-related cancers creates a distorted picture of risk. Public health discussions require balance, not selective amplification.
Mental Health Requires Nuance, Not Simplification
You reference increases in cannabis-linked paranoia and psychotic disorders. This topic deserves care and nuance.
Mental health outcomes are complex. Many individuals who experience psychosis have underlying conditions that predate cannabis use. Correlation does not equal causation.
Alcohol, meanwhile, is strongly associated with depression, suicide, domestic violence, and assault. Tobacco use is disproportionately high among people with severe mental illness and is a major contributor to reduced life expectancy in those populations.
The presence of risk does not justify singling out cannabis while normalizing far more destructive substances.
Impaired Driving Is a Law Enforcement Issue, Not a Cannabis Issue
Driving under the influence of any substance is dangerous. Cannabis should not be treated differently than alcohol or prescription medications in this regard.
Alcohol remains the leading cause of impaired driving deaths in the United States by a wide margin. Cannabis-related impairment should be addressed through enforcement, education, and improved testing methods, not through fear-based narratives that exaggerate its relative impact.
“Big Weed” Is Not the Industry You Describe
Your editorial leans heavily on the concept of “Big Weed,” implying a monolithic, deceptive industry modeled after Big Tobacco.
That framing does not reflect reality.
The cannabis industry remains fragmented, heavily regulated, and largely composed of small and mid-sized operators. Advertising is restricted. Banking access is limited. Federal prohibition still exists. Compliance costs are significant.
If deceptive medical claims or child-targeted packaging exist, regulators already have tools to address them. Those are enforcement failures, not arguments against legalization or responsible operators.
Conflating small craft brands with hypothetical corporate bad actors obscures more than it reveals.
Taxation Without Federal Reform Creates Harm
You propose higher cannabis taxes as a solution to excessive use. This ignores the realities of a federally illegal market.
Excessive taxation drives consumers to the illicit market. That market does not test products, label potency, or restrict access. It increases harm, not reduces it.
Alcohol and tobacco taxes work because those substances are federally legal, nationally regulated, and consistently enforced. Cannabis does not yet have that framework.
Raising taxes without fixing federal policy does not protect public health. It undermines it.
Potency Caps Are Not Evidence-Based
Your suggestion to ban cannabis products above 60 percent THC lacks scientific consensus.
Potency alone does not determine harm. Dose, frequency, tolerance, delivery method, and education matter far more. High-potency products often allow experienced consumers to use less, not more.
Alcohol provides a useful comparison. Beer, wine, and spirits coexist under regulation. Education and labeling manage risk more effectively than arbitrary bans.
Medical Cannabis Deserves Honesty, Not Dismissal
Your editorial claims that decades of research have found little medical benefit from cannabis. That statement oversimplifies a complex body of evidence.
Cannabis has demonstrated benefits for pain management, nausea, appetite stimulation, spasticity, and certain seizure disorders. It is not a cure-all, but neither are most pharmaceuticals.
The appropriate response to false medical claims is enforcement, not delegitimization of a therapeutic option many patients rely on.
Social Justice Cannot Be a Footnote
You acknowledge the racial disparities of cannabis prohibition, then move on.
For communities that lived through decades of disproportionate arrests, incarceration, and economic exclusion, this is not a side note. It is the core issue.
Any move toward “grudging toleration” that increases enforcement, penalties, or barriers risks recreating those harms under a different name.
Cannabis Is Already Heavily Regulated
The idea that the United States legalized cannabis without regulating it is incorrect.
Cannabis is among the most regulated consumer products in America. Testing, tracking, labeling, licensing, security, and advertising restrictions exceed those placed on alcohol and tobacco.
The problem is not lack of regulation. It is inconsistent federal policy and lingering cultural discomfort.
A Call for Proportionality and Consistency
Silly Nice does not argue that cannabis should be promoted without limits. We believe in education, transparency, lab testing, and responsible adult use.
What we reject is the application of a harsher moral and regulatory standard to cannabis than to substances that kill hundreds of thousands of Americans every year.
If society is going to reassess substance policy honestly, it must do so consistently.
Start with alcohol. Start with tobacco. Apply the same scrutiny, the same urgency, and the same concern for public health.
Anything less is not balance. It is bias.
Closing
Cannabis policy should be guided by evidence, proportional harm, and respect for human experience. It should acknowledge risks without inflating them and freedoms without ignoring responsibility.
We invite the New York Times to engage in that conversation with the same rigor it applies elsewhere.
Sincerely,
Silly Nice